VEGFA and cancer: Respecting the pivotal role of the VEGF/VEGFR signaling axis in cancer angiogenesis, several anti-angiogenic medicines have been authorized for various types of cancer, such as anti-VEGF antibodies, anti-VEGFR antibodies, and VEGFR tyrosine kinase inhibitors (TKIs) (Fig. 1) [14, 21].